Dana Gaffney

Fifth Ovarian Cancer Consensus Conference of the Gynecologic Cancer InterGroup: recurrent disease

Michelle Wilson, Éric Pujade-Lauraine, Daisuke Aoki et al. · Annals of Oncology · 2016 · 296 citations · Full text

Medicine, Gynecology, Oncology +16

Oncogenic Characterization and Pharmacologic Sensitivity of Activating Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations to the Selective FGFR Inhibitor Erdafitinib

Jayaprakash D. Karkera, Gabriela Martinez Cardona, Katherine Bell et al. · Molecular Cancer Therapeutics · 2017 · 64 citations

Medicine, Oncology, Pharmacology +17

Abstract 4859: JNJ-64619178, a selective and pseudo-irreversible PRMT5 inhibitor with potent <i>in vitro</i> and <i>in vivo</i> activity, demonstrated in several lung cancer models

Tongfei Wu, Hillary J. Millar, Dana Gaffney et al. · Cancer Research · 2018 · 25 citations

Medicine, Molecular Biology, Oncology +16

Abstract DDT02-04: A novel PRMT5 inhibitor with potent in vitro and in vivo activity in preclinical lung cancer models

Dirk Brehmer, Tongfei Wu, Geert Mannens et al. · Cancer Research · 2017 · 20 citations

Medicine, Oncology, Pharmacology +13

Prespecified Candidate Biomarkers Identify Follicular Lymphoma Patients Who Achieved Longer Progression-Free Survival with Bortezomib–Rituximab Versus Rituximab

Bertrand Coiffier, Weimin Li, Erin D. Henitz et al. · Clinical Cancer Research · 2013 · 18 citations · Full text

Medicine, Hematology, Oncology +17